BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17174585)

  • 1. When should we use TNF antagonists in children with rheumatic disease?
    Quartier P
    Joint Bone Spine; 2007 Jan; 74(1):1-3. PubMed ID: 17174585
    [No Abstract]   [Full Text] [Related]  

  • 2. Trials reveal promising options for treating juvenile rheumatoid arthritis.
    Hampton T
    JAMA; 2008 Jan; 299(1):27-8. PubMed ID: 18167400
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 4. Juvenile idiopathic arthritis: current and future treatment options.
    Martini G; Zulian F
    Expert Opin Pharmacother; 2006 Mar; 7(4):387-99. PubMed ID: 16503811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.
    Shenoi S; Wallace CA
    Paediatr Drugs; 2010 Dec; 12(6):367-77. PubMed ID: 21028916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract]   [Full Text] [Related]  

  • 7. [Biological therapy treatment of juvenile idiopathic arthritis].
    Herlin T
    Ugeskr Laeger; 2008 Jun; 170(24):2105-8. PubMed ID: 18565289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-TNF therapy in rheumatoid arthritis].
    Yakeuchi T; Amano K
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Feb; 27(1):7-15. PubMed ID: 15045810
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].
    Amano K
    Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2966-71. PubMed ID: 22175139
    [No Abstract]   [Full Text] [Related]  

  • 10. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al.
    Neovius M; Askling J
    Ann Rheum Dis; 2014 Jun; 73(6):e32. PubMed ID: 24638970
    [No Abstract]   [Full Text] [Related]  

  • 12. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
    Kilic O; Kasapcopur O; Camcioglu Y; Cokugras H; Arisoy N; Akcakaya N
    Rheumatol Int; 2012 Sep; 32(9):2675-9. PubMed ID: 21789614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric rheumatology: JIA, treatment and possible risk of malignancies.
    Ruperto N; Martini A
    Nat Rev Rheumatol; 2011 Jan; 7(1):6-7. PubMed ID: 21135880
    [No Abstract]   [Full Text] [Related]  

  • 15. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biologicals in the treatment of rheumatic diseases].
    Scherer HU; Burmester GR
    Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors.
    Anderson P; Louie J; Lau A; Broder M
    Curr Rheumatol Rep; 2005 Mar; 7(1):3-9. PubMed ID: 15760575
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
    Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
    Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retention on anti-tumour necrosis factor therapy: the Waikato experience.
    Ip K; Hartley L; Solanki K; White D
    N Z Med J; 2015 May; 128(1415):34-40. PubMed ID: 26117510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-target activity of TNF-alpha inhibitors characterized by protein biochips.
    Feyen O; Lueking A; Kowald A; Stephan C; Meyer HE; Göbel U; Niehues T
    Anal Bioanal Chem; 2008 Jul; 391(5):1713-20. PubMed ID: 18344017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.